Association of HER2 ECD and t-PSA serum levels for possible breast cancer diagnosis

Sensing and Bio-Sensing Research

Volumn 2, Issue , 2014, Pages 1-7

  Chang, Ying Feng ^a   Hung, Shuo Hui ^b,c   Su, Li Chen ^a,d   Chen, Ran Chou ^b,c   Chou, Chien ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Biomarker panel; Biosensor; Breast cancer; HER2 ECD; PSA

Indexed keywords

EID: 84919435927     PISSN: None     EISSN: 22141804     Source Type: Journal    
DOI: 10.1016/j.sbsr.2014.08.003     Document Type: Article

References (51)

1. Arslan N., Serdar M., Deveci S., Ozturk B., Narin Y., Ilgan S., Ozturk E., Ozguven M.A. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. Ann. Nucl. Med. 2000, 14:395-399.
2. Mbeunkui F., Metge B.J., Shevde L.A., Pannell L.K. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J. Proteome Res. 2007, 6:2993-3002.
3. Bernstein J.L., Godbold J.H., Raptis G., Watson M.A., Levinson B., Aaronson S.A., Fleming T.P. Identification of mammaglobin as a novel serum marker for breast cancer. Clin. Cancer Res. 2005, 11:6528-6535.
4. Chang Y.F., Hung S.H., Lee Y.J., Chen R.C., Su L.C., Lai C.S., Chou C. Discrimination of breast cancer by measuring prostate-specific antigen levels in women's serum. Anal. Chem. 2011, 83:5324-5328.
5. Hideshima S., Sato R., Inoue S., Kuroiwa S., Osaka T. Detection of tumor marker in blood serum using antibody-modified field effect transistor with optimized BSA blocking. Sens. Actuators, B 2012, 161:146-150.
6. Tothill I.E. Biosensors for cancer markers diagnosis. Semin. Cell Dev. Biol. 2009, 20:55-62.
7. Chang Y.T., Wu C.C., Shyr Y.M., Chen T.C., Hwang T.L., Yeh T.S., Chang K.P., Liu H.P., Liu Y.L., Tsai M.H., Chang Y.S., Yu J.S. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS ONE 2011, 6:e20029.
8. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., Yue L., Bray-Ward P., Ward D.C. Serum protein markers for early detection of ovarian cancer. Proc. Nat. Acad. Sci. U.S.A. 2005, 102:7677-7682.
9. Polanski M., Anderson N.Leigh A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 2006, 1:1-48.
10. Gonzalez R.M., Daly D.S., Tan R., Marks J.R., Zangar R.C. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1543-1551.
11. Leyland-Jones B., Smith B.R. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol. 2011, 12:286-295.
12. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
13. Monne M., Croce C.M., Yu H., Diamandis E.P. Molecular characterization of prostate-specific antigen messenger-RNA expressed in breast-tumors. Cancer Res. 1994, 54:6344-6347.
14. Carder P.J., Speirs V., Ramsdale J., Lansdown M.R. Expression of prostate specific antigen in male breast cancer. J. Clin. Pathol. 2005, 58:69-71.
15. Narita D., Raica M., Suciu C., Cimpean A., Anghel A. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer. Folia Histochem. Cytobiol. 2006, 44:165-172.
16. Sauter E.R., Lininger J., Magklara A., Hewett J.E., Diamandis E.P. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk,. Int. J. Cancer 2004, 108:588-591.
17. Yu H., Levesque M.A., Clark G.M., Diamandis E.P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin. Cancer Res. 1998, 4:1489-1497.
18. Narita D., Anghel A., Motoc M. Prostate-specific antigen may serve as a pathological predictor in breast cancer. Rom. J. Morphol. Embryol. 2008, 49:173-180.
19. Kraus T.S., Cohen C., Siddiqui M.T. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn. Pathol. 2010, 5:6.
20. Mohammadizadeh F., Ranaee M., Zavareh M.H., Faghihi M., Saremi M., Eftekhari M. The expression of prostate-specific antigen in invasive breast carcinoma and its relationship with routine clinicopathologic parameters. Adv. Biomed. Res. 2012, 1:55.
21. Black M.H., Giai M., Ponzone R., Sismondi P., Yu H., Diamandis E.P. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin. Cancer Res. 2000, 6:467-473.
22. Radowicki S., Kunicki M., Bandurska-Stankiewicz E. Prostate-specific antigen in the serum of women with benign breast disease. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 138:212-216.
23. Chen S.H., Hsu Y.P., Lu H.Y., Ho J.A. Gold/phospholipid nanoconstructs as label-free optical probes for evaluating phospholipase A2 activity. Biosens. Bioelectron. 2014, 52:202-208.
24. Li C.T., Chen H.F., Un I.W., Lee H.C., Yen T.J. Study of optical phase transduction on localized surface plasmon resonance for ultrasensitive detection. Opt. Express 2012, 20:3250-3260.
25. Chang T.C., Wu C.C., Wang S.C., Chau L.K., Hsieh W.H. Using a fiber optic particle plasmon resonance biosensor to determine kinetic constants of antigen-antibody binding reaction. Anal. Chem. 2013, 85:245-250.
26. Huang Y.C., Chiang C.Y., Li C.H., Chang T.C., Chiang C.S., Chau L.K., Huang K.W., Wu C.W., Wang S.C., Lyu S.R. Quantification of tumor necrosis factor-alpha and matrix metalloproteinases-3 in synovial fluid by a fiber-optic particle plasmon resonance sensor. Analyst 2013, 138:4599-4606.
27. Lin H.Y., Huang C.H., Chen S.H., Liu Y.C., Chang W.Z., Chau L.K. Tubular waveguide evanescent field absorption biosensor based on particle plasmon resonance for multiplex label-free detection. Biosens. Bioelectron. 2013, 41:268-274.
28. Lin H.Y., Huang C.H., Lu S.H., Kuo I.T., Chau L.K. Direct detection of orchid viruses using nanorod-based fiber optic particle plasmon resonance immunosensor. Biosens. Bioelectron. 2014, 51:371-378.
29. Liao W.C., Ho J.A.A. Improved activity of immobilized antibody by paratope orientation controller: probing paratope orientation by electrochemical strategy and surface plasmon resonance spectroscopy. Biosens. Bioelectron. 2014, 55:32-38.
30. Morton S.M., Silverstein D.W., Jensen L. Theoretical studies of plasmonics using electronic structure methods. Chem. Rev. 2011, 111:3962-3994.
31. Geddes C.D., Gryczynski I., Malicka J., Gryczynski Z., Lakowicz J.R. Metal-enhanced fluorescence: potential applications in HTS. Comb. Chem. High Throughput Screen 2003, 6:109-117.
32. Chang Y.F., Chen R.C., Lee Y.J., Chao S.C., Su L.C., Li Y.C., Chou C. Localized surface plasmon coupled fluorescence fiber-optic biosensor for alpha-fetoprotein detection in human serum. Biosens. Bioelectron. 2009, 24:1610-1614.
33. Chang Y.F., Wang S.F., Huang J.C., Su L.C., Yao L., Li Y.C., Wu S.C., Chen Y.M., Hsieh J.P., Chou C. Detection of swine-origin influenza A (H1N1) viruses using a localized surface plasmon coupled fluorescence fiber-optic biosensor. Biosens. Bioelectron. 2010, 26:1068-1073.
34. Chang Y.F., Yu J.S., Chang Y.T., Su L.C., Wu C.C., Chang Y.S., Lai C.S., Chou C. The utility of a high-throughput scanning biosensor in the detection of the pancreatic cancer marker ULBP2. Biosens. Bioelectron. 2013, 41:232-237.
35. Chao C.-H., Chang Y.-F., Chen H.-C., Lin L.-Y., Yu P.-C., Chang Y.-S., Lee Y.-J., Chou C. Detection of urine cofilin-1 from patients hospitalized in the intensive care unit using the metal-enhanced fluorescence technique. Sens. Actuators, B 2012, 173:184-190.
36. Hsieh B.Y., Chang Y.F., Ng M.Y., Liu W.C., Lin C.H., Wu H.T., Chou C. Localized surface plasmon coupled fluorescence fiber-optic biosensor with gold nanoparticles. Anal. Chem. 2007, 79:3487-3493.
37. Huang J.C., Chang Y.F., Chen K.H., Su L.C., Lee C.W., Chen C.C., Chen Y.M., Chou C. Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in human serum using a localized surface plasmon coupled fluorescence fiber-optic biosensor. Biosens. Bioelectron. 2009, 25:320-325.
38. Su L.C., Chang Y.F., Chou C., Ho J.A., Li Y.C., Chou L.D., Lee C.C. Binding kinetics of biomolecule interaction at ultralow concentrations based on gold nanoparticle enhancement. Anal. Chem. 2011, 83:3290-3296.
39. Chang Y.F., Chao C.H., Lin L.Y., Tsai C.H., Chou C., Lee Y.J. Determination of urine cofilin-1 level in acute kidney injury using a high-throughput localized surface plasmon-coupled fluorescence biosensor. J. Biomed. Opt. 2014, 19:6.
40. Ng M.Y., Liu W.C. Fluorescence enhancements of fiber-optic biosensor with metallic nanoparticles. Opt. Express 2009, 17:5867-5878.
41. Yu C.-J., Lin C.-E., Teng H.-K., Tsai C.-C., Chou C. Dual-frequency paired polarization phase shifting ellipsometer. Opt. Commun. 2009, 282:1516-1520.
42. Kong S.Y., Nam B.H., Lee K.S., Kwon Y., Lee E.S., Seong M.W., Lee do H., Ro J. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin. Chem. 2006, 52:1510-1515.
43. Sartippour M.R., Zhang L., Lu M., Wang H.J., Brooks M.N. Nipple fluid basic fibroblast growth factor in patients with breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2995-2998.
44. Harman S.M., Gucciardo F., Heward C.B., Granstrom P., Barclay-White B., Rogers L.W., Ibarra J.A. Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2310-2315.
45. Fenton J.J., Taplin S.H., Carney P.A., Abraham L., Sickles E.A., D'Orsi C., Berns E.A., Cutter G., Hendrick R.E., Barlow W.E., Elmore J.G. Influence of computer-aided detection on performance of screening mammography. N. Engl. J. Med. 2007, 356:1399-1409.
46. Hendrick R.E., Cole E.B., Pisano E.D., Acharyya S., Marques H., Cohen M.A., Jong R.A., Mawdsley G.E., Kanal K.M., D'Orsi C.J., Rebner M., Gatsonis C., Grp D.I. Accuracy of soft-copy digital mammography versus that of screen-film mammography according to digital manufacturer: ACRIN DMIST retrospective multireader study. Radiology 2008, 247:38-48.
47. Gion M., Mione R., Leon A.E., Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin. Chem. 1999, 45:630-637.
48. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes D.F., Bast R.C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25(2007):5287-5312.
49. Kanojia D., Garg M., Gupta S., Gupta A., Suri A. Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2009, 18:630-639.
50. Ellis M.J., Ding L., Shen D., Luo J.Q., Suman V.J., Wallis J.W., Van Tine B.A., Hoog J., Goiffon R.J., Goldstein T.C., Ng S., Lin L., Crowder R., Snider J., Ballman K., Weber J., Chen K., Koboldt D.C., Kandoth C., Schierding W.S., McMichael J.F., Miller C.A., Lu C., Harris C.C., McLellan M.D., Wendl M.C., DeSchryver K., Allred D.C., Esserman L., Unzeitig G., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Leitch M., Hunt K., Olson J., Tao Y., Maher C.A., Fulton L.L., Fulton R.S., Harrison M., Oberkfell B., Du F.Y., Demeter R., Vickery T.L., Elhammali A., Piwnica-Worms H., McDonald S., Watson M., Dooling D.J., Ota D., Chang L.W., Bose R., Ley T.J., Piwnica-Worms D., Stuart J.M., Wilson R.K., Mardis E.R. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
51. Schulze A., Harris A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012, 491:364-373.